menu
    • menu
    [{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"XVR011","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExeVir Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"XVR011","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ExeVir Bio \/ ExeVir Bio","highestDevelopmentStatusID":"7","companyTruncated":"ExeVir Bio \/ ExeVir Bio"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"XVR011","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ExeVir Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"7","companyTruncated":"ExeVir Bio \/ VIB"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"XVR012","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ European Investment Bank","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ European Investment Bank"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"XVR012","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"VHH72-FC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Undisclosed"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"XVR021","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"XVR013","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ VIB"}]

    Find Clinical Drug Pipeline Developments & Deals by ExeVir Bio

    Menu

    ExeVir Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR012,XVR014

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ExeVir Bio Reveals Positive Virus Neutralization Data for XVR012 Against Omicron Variants

                            Details : XVR012 is a cocktail of XVR013m and XVR014, targets three distinct epitopes. It is currently being evaluated in preclinical studies for the treatment of Covid-19 infection.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 15, 2024

                            Lead Product(s) : XVR012,XVR014

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR012

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : European Investment Bank

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ExeVir Bio Secures EUR 25 Million Venture Debt Financing from The European Investment Bank

                            Details : The EIB financing will help to advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19. XVR012, is a potent COVID-19 neutralizing antibody that targets the S1 and S2 region of the coronavirus.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 01, 2023

                            Lead Product(s) : XVR012

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : European Investment Bank

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR021

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Flanders Innovation & Entrepreneurship

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

                            Details : The funding will be used by ExeVir for pre-clinical research towards prophylactic and therapeutic solutions including, XVR021 for dengue by leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibod...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : XVR021

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Flanders Innovation & Entrepreneurship

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR013

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : VIB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

                            Details : XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 13, 2023

                            Lead Product(s) : XVR013

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : VIB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ExeVir and Mithra Announce Manufacturing Collaboration for Innovative Covid-19 Treatments

                            Details : XVR011 is a single domain-based anti-SARS-CoV-2 antibody (llama-derived VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 15, 2021

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVI...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : VIB

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

                            Details : Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 16, 2021

                            Lead Product(s) : XVR011

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : VIB

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed

                            ExeVir Bio

                            Belgium arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VHH72-FC

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $27.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

                            Details : Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : VHH72-FC

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $27.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth